Hancock Jaffe Laboratories (NASDAQ: HJLI) is one of 125 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its rivals? We will compare Hancock Jaffe Laboratories to related companies based on the strength of its valuation, earnings, risk, dividends, institutional ownership, analyst recommendations and profitability.
Earnings and Valuation
This table compares Hancock Jaffe Laboratories and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Hancock Jaffe Laboratories||$190,000.00||-$13.04 million||-0.51|
|Hancock Jaffe Laboratories Competitors||$1.45 billion||$147.44 million||53.76|
This is a breakdown of recent recommendations and price targets for Hancock Jaffe Laboratories and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Hancock Jaffe Laboratories||0||0||0||0||N/A|
|Hancock Jaffe Laboratories Competitors||914||3045||5205||267||2.51|
As a group, “Surgical & medical instruments” companies have a potential upside of 15.16%. Given Hancock Jaffe Laboratories’ rivals higher probable upside, analysts clearly believe Hancock Jaffe Laboratories has less favorable growth aspects than its rivals.
This table compares Hancock Jaffe Laboratories and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Hancock Jaffe Laboratories||-5,161.19%||-302.90%||-182.37%|
|Hancock Jaffe Laboratories Competitors||-796.22%||-109.66%||-22.13%|
Institutional and Insider Ownership
1.1% of Hancock Jaffe Laboratories shares are held by institutional investors. Comparatively, 50.2% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 15.6% of shares of all “Surgical & medical instruments” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Hancock Jaffe Laboratories rivals beat Hancock Jaffe Laboratories on 9 of the 9 factors compared.
About Hancock Jaffe Laboratories
Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prosthetic heart valve designed to mimic and function like a native heart valve; the CoreoGraft, a device for use as an alternate or supplemental coronary vascular conduit in coronary bypass surgery; and the Venous Valve, a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency. The company was founded in 1987 and is headquartered in Irvine, California. As of July 18, 2006, Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.
Receive News & Ratings for Hancock Jaffe Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hancock Jaffe Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.